Earnings Call Summary | Altamira Therapeutics Ltd(CYTOF.US) Q4 2024 Earnings Conference
The following is a summary of the Altamira Therapeutics Ltd. (CYTOF) Q4 2024 Earnings Call Transcript:
以下是Altamira Therapeutics Ltd.（CYTOF）2024年第四季度业绩会会议记录的摘要：
Financial Performance:
财务表现：
Altamira reported an increase in total operating loss from continuing operations to $6.9 million in 2024 from $6.6 million in 2023.
Research and development expenses increased slightly to $3.7 million in 2024 from $3.4 million in 2023, while General and Administrative expenses decreased to $3.2 million from $3.5 million.
The company reported a net loss of $8.5 million for 2024, deepening from $4.3 million in the previous year.
Altamira报告称，2024年持续经营总运营亏损增加至690万，而2023年为660万。
研发费用从2023年的340万小幅增加至2024年的370万，而一般和行政费用从350万减少至320万。
公司报告称，2024年净亏损为850万，较前一年的430万进一步加深。
Business Progress:
业务进展:
RNA delivery business continued gaining momentum with new partnerships and developments in proprietary platforms like OligoPhore, SemaPhore, and the novel CycloPhore for circular RNA.
Initiated a partial spin-off plan for its RNA delivery subsidiary (ATAG) to manage finance through private equity, transitioning away from public markets due to the Nasdaq delisting.
RNA递送业务在新合作伙伴关系和专有平台（如OligoPhore、SemaPhore和新型CycloPhore用于环状RNA）的开发中持续获得动力。
为其RNA递送子公司（ATAG）启动部分剥离计划，以通过股权投资来管理资金，因纳斯达克退市，逐步脱离公开市场。
Opportunities:
机会：
Pursued further partnerships in the growing global market for RNA therapeutics and diagnostics, including a new collaboration in the radiopharmaceutical sector targeting cancer treatments.
Protection of IP with provisional patents such as for CycloPhore, potentially opening up licensing opportunities.
在不断增长的全球RNA治疗和诊断市场中，进一步追求合作伙伴关系，包括在针对癌症治疗的放射药物板块的新合作。
通过临时专利保护知识产权，例如针对CycloPhore的专利，可能会开启许可机会。
Risks:
风险：
Delisting from Nasdaq posed major challenges for capital raising, necessitating a shift to private funding models and potential restructuring.
从纳斯达克退市给融资带来了重大挑战，迫使我们转向股权投资模型和潜在的重组。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容的准确性无法完全保证。有关更全面的详情，请参考IR网站。文章仅供投资者参考，不构成任何指导或推荐建议。
译文内容由第三方软件翻译。
